three different pathogenic species of B. burgdorferi sensu lato causing LB in Europe (23, 24) . Among individual borrelial proteins from different species, sequence heterogeneity varies up to 40% (8, 21, 33, 35) , and their use as antigens may affect the sensitivity of the assays (18) (19) (20) .
In hopes of increasing the specificity of serodiagnosis, a number of borrelial recombinant proteins have been tested (an 83-kDa protein, flagellin, OspA, OspB, OspC, OspE, OspF, p22, BBK32, VlsE, and P39) (10, 17, 25-28, 31, 32, 35) . So far, none of them has proved superior to the current routine serology.
Decorin binding protein A (DbpA), a borrelial outer surface protein, is one of the key proteins in B. burgdorferi. DbpA elicits a strong antibody response during experimental murine borreliosis and has been suggested as a potential vaccine protein (6, 9, 14, 15) . DbpA has not, however, been tested in the serodiagnosis of human LB.
We therefore tested DbpA in the serodiagnosis of LB. dbpA was cloned and sequenced from the three European pathogenic borrelial species, B. burgdorferi sensu stricto, B. afzelii and B. garinii. The respective recombinant DbpAs (rDbpA) were thereafter evaluated as antigens in WB and in ELISA.
MATERIALS AND METHODS
Bacterial strains. Finnish borrelial strains were received from Matti Viljanen (National Public Health Institute, Turku, Finland). B. burgdorferi sensu stricto IA was isolated from cerebrospinal fluid of a Finnish patient with neuroborreliosis (NB), and B. afzelii A91 and B. garinii 40 were isolated from skin biopsy samples of Finnish patients with LB. B. afzelii A91 and B. garinii 40 are low-passage strains, and B. burgdorferi sensu stricto IA is a high-passage strain. The strains were genotyped by PCR and sequencing, the target DNA being a fragment from the flagellin gene of B. burgdorferi (24) . B. afzelii strain SK1 was used in our in-house ELISA to detect antibodies against borrelial WCL proteins. Borrelia cells were cultivated in Barbour-Stoenner-Kelly (BSK-H) medium (Sigma, St.
Louis, Mo.) at 33°C in 5% CO 2 . The Escherichia coli host cell strains used for cloning and expression of recombinant proteins were INF␣F (Invitrogen, Leek, The Netherlands) and M15 (Qiagen, Hilden, Germany), respectively.
DNA purification. Borrelial genomic DNA was purified with a Dneasy tissue kit (Qiagen). Purified DNA was used in PCR and cloning experiments. Plasmid DNA was purified with a QIAprep-spin plasmid kit (Qiagen).
PCR and DNA sequencing. A PCR-based approach was employed to amplify and sequence the dbpA alleles from three different isolates of B. burgdorferi sensu lato, B. burgdorferi sensu stricto, B. afzelii A91, and B. garinii 40. Primers for dbpA PCR amplification were designed on the basis of published dbpA sequences (Table 1) . Several primer pairs were designed and tested to ensure that the entire coding sequence of the dbpA was obtained. To eliminate any errors possibly made by Taq polymerase, the two strands of each dbpA were sequenced independently at least twice. Expression primers for each strain encoding the mature portion of the DbpA protein after cysteine at the site of posttranslational acylation were chosen from the analyzed sequences. Approximately 1 ng of template DNA was used under standard PCR conditions: 30 cycles of 94°C denaturing for 1 min, 50°C annealing for 1 min, and 72°C extension for 1 min 30 s with AmpliTaq Gold DNA polymerase (Perkin-Elmer, Norwalk, Conn.). The PCR amplified full-length or partial dbpA was cloned to the pCR 2.1-TOPO vector (Invitrogen) for sequencing. DNA sequencing was performed at the Core Facility of the Haartman Institute, University of Helsinki, with a DyePrimer (T7, M13Rev) cycle sequencing kit (Applied Biosystems, Inc., Foster City, Calif.). Sequencing reactions were run and analyzed by the automated sequencing apparatus model 373A (Applied Biosystems Inc.). DNA and protein sequences were analyzed with Lasergene software (DNASTAR, Inc., Madison, Wis.).
Cloning and expression of DbpA. For expression of recombinant DbpA (rDbpA), six-His-tagged protein constructs were generated. The forward and reverse primers included a BamHI site and a KpnI site, respectively. The PCR-amplified DNA encoding the mature portion of DbpA was cloned into pCR 2.1-TOPO plasmid (Invitrogen). The recombinant plasmid was purified and digested with BamHI and KpnI restriction enzymes. The cleaved dbpA was then ligated to a similarly digested pQE-30 expression plasmid (Qiagen) and transformed into E. coli M15 host cells. The transformation mixture was plated onto Luria-Bertani plates containing 100 g of ampicillin per ml. A primary culture for expression of the DbpA construct was started by inoculating a single colony from a fresh transformant plate into 50 ml of Luria-Bertani broth containing 100 g of ampicillin per ml. The culture was incubated at 37°C with shaking overnight. After 1:50 dilution, 1,500 ml of Luria-Bertani broth containing 100 g of ampicillin per ml was incubated at 37°C for 3 h (until growth reached the mid-log phase; the optical density at 600 nm [OD 600 ] was ca. 0.6). Isopropyl-␤-D-thiogalactoside was added to a final concentration of 0.7 mM, and the mixture was incubated for a further 3 h. The cells were centrifuged at 8,000 rpm in a superspeed centrifuge, Sorvall RC-5B Plus; DuPont Company, Wilmington, Del.) for 10 min, washed with phosphate-buffered saline (PBS), and sonicated in PBS with a Soniprep 150 sonicator (Sanyo, Japan) for 5 min, and centrifuged at 13,000 rpm. The sonicate supernatant containing the rDbpA protein was applied to a Chelating Sepharose Fast Flow column (Pharmacia, Sweden) containing Ni 2ϩ ions. rDbpA was eluted from the column by increasing the amount of imidazole. The expression and purity of the rDbpA was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoblotting. rDbpAs originating from B. burgdorferi sensu stricto IA, B. afzelii A91, or B. garinii 40 (referred to here as rDbpA Bbia , rDbpA BaA91 , and rDbpA Bg40 , respectively) were fractionated in SDS-PAGE (12.5% polyacrylamide) and transferred to a nitrocellulose membrane (Bio-Rad; 0.2-m pore size) by semidry transfer with 40 mM glycine-50 mM Tris (pH 9.0)-0.375% (wt/vol) SDS-20% (vol/vol) methanol buffer. Twelve micrograms of each rDbpA was used for one 7-cm-wide nitrocellulose membrane. The nitrocellulose membranes were cut to approximately 2-mm strips which were soaked in 0.1% Tween 20-0.9% NaCl. Serum samples were diluted in 0.1% Tween 20, 0.9% NaCl, 0.1 g of fat-free bovine milk powder per liter (Valio, Helsinki, Finland). Samples were incubated at a 1:100 dilution for 2 h. After four buffer rinses for a total of 20 min, the blots were incubated with alkaline phosphatase-conjugated rabbit anti-human immunoglobulin G (IgG) (Jackson Immuno Research Laboratories, Inc., West Grove, Pa.) at 1:5,000 for 2 h. The secondary antibody for immunoblots with plasma from mice infected with B. garinii was alkaline phosphatase-conjugated rabbit anti-mouse IgG (Orion, Espoo, Finland). After washing, the bands were visualized with 5-bromo-4-chloro-3-indolylphosphate-nitro blue tetrazolium (Sigma Chemical Co.). The reaction was terminated 10 to 15 min later by washing with distilled water.
ELISA. For ELISAs measuring anti-DbpA antibodies, the wells in a microtiter plate were coated with 100 l (2 g/ml) of variant recombinant DbpA proteins . Clinical diagnosis of all patients was confirmed in ELISA by demonstrating antibodies in serum against WCL from B. afzelii strain SK1 (inhouse ELISA) and flagella (DAKO, Glostrup, Denmark), as described earlier (36) . Serum samples from five patients with syphilis, five rheumatoid factor (RF)-positive serum samples, five Epstein-Barr virus (EBV) IgM-positive serum samples, and five serum samples from healthy blood donors were used as controls.
For ELISA analyses, we collected human serum samples from 14 patients with NB, 15 patients with LA, and 23 patients with culture-or PCR-positive EM (B. afzelii, n ϭ 17; B. garinii, n ϭ 4, and genotyping not feasible, n ϭ 2). In patients with NB and LA, the diagnosis was confirmed serologically, as in samples for WB. From the EM patients, serum samples were taken at diagnosis and 1 to 3 months posttreatment. Serum samples from patients with syphilis, systemic lupus erythematosus (SLE), RF positivity, antistreptolysin (ASO) positivity, or EBV infection and from healthy blood donors were used as controls.
Plasma samples from mice infected with B. garinii strain Å218 were obtained from Matti Viljanen (National Public Health Institute, Turku, Finland). The infection was verified by culturing ear pinnae from each mouse at each time point when groups of five mice were sacrificed. Plasma from individual infected mice was pooled at time points 2, 4, 8, and 16 weeks postinfection.
Nucleotide sequence accession number. The nucleotide sequences for the dbpA were submitted to GenBank under the following accession numbers: (B. afzelii A91, XXX; B. garinii 40, YYY; and B. burgdorferi sensu stricto IA, ZZZ). Published dbpA sequences from B. burgdorferi sensu lato strains BO23 (AF069267), ACA1 (AF069278), PGau (AF069270), U01 (AF069284), Ip90 (AF069258), VSBP (AF069272), PBr (AF069281), JEM4 (AF079362), 297 (U75866), LP4 (AF069271), MC1 (AF079361), HB19 (AF069254), B31 (AF069269), and N40 (AF069252) were obtained from GenBank.
RESULTS

Sequence analysis of DbpA of the Finnish borrelial isolates.
The deduced mature portions of DbpA BaA91 , DbpA Bg40 , and DbpA Bbia contained 150, 165, and 167 residues, respectively ( Fig. 1) . Differences in the amino acid sequences were distributed along the entire sequence, but deletions in DbpA BaA91 were near the carboxy terminus. (Fig. 2) .
B. afzelii sequence analyses. The amino acid sequence of DbpA BaA91 was compared with the published human B. afzelii DbpA sequences from the BO23 (AF069267), ACA1 (AF069278), PGau (AF069270), and U01 (AF069284) strains (Fig. 2) . The percentages of deduced mature amino acid sequence identity among them ranged from 45 to 100%. DbpA BaA91 protein was identical to that in strain ACA1. The DbpA sequences in strains PGau and U01 showed the highest divergence among the B. afzelii strains: 45.9 and 45.3% identity to DbpA BaA91 , respectively. The DbpA BaA91 sequence was also compared with four published outer surface protein 17 (Osp17) sequences from European B. afzelii strains (22) . The identity between DbpA BaA91 and the four Osp17 sequences ranged from 88.2 to 100%. The differences in DbpA and Osp17 sequences of B. afzelii strains were evenly spread along the protein.
B. garinii sequence analyses. The DbpA Bg40 sequence was compared with published B. garinii DbpA sequences from the Ip90 (AF069258), VSBP (AF069272), PBr (AF069281), and JEM4 (AF079362) strains (Fig. 2) . The identity ranged from B. burgdorferi sensu stricto sequence analyses. The DbpA Bbia sequence was compared with published DbpA sequences of human B. burgdorferi sensu stricto from the 297 (U75866), LP4 (AF069271), MC1 (AF079361), and HB19 (AF069254) strains and with two sequences from the tick isolates B31 (AF069269) and N40 (AF069252) (Fig. 2) . The deduced mature amino acid sequence identity ranged from 76.3 to 100%. The dbpA sequence in B. burgdorferi sensu stricto IA differs by only one nucleotide (position 100) from the dbpA sequence of strain B31, which does not change the translated amino acid sequence.
Immunoblot reactivity of LB patient samples. Serum samples from 16 of the 20 LB patients were positive in immunoblots with rDbpA BaA91 , rDbpA Bg40 , and rDbpA Bbia as antigens ( Table 2 ). Nine of the 10 patients with NB reacted positively; 4 samples showed immunoreactivity with rDbpA BaA91 , 5 with rDbpA Bg40 , and 2 with rDbpA Bbia . Two samples recognized two rDbpAs each-one rDbpA BaA91 and rDbpA Bg40 and the other rDbpA BaA91 and rDbpA Bbia . Seven of the 10 samples from patients with LA were positive; 5 with rDbpA BaA91 , 3 with rDbpA Bg40 , and 2 with rDbpA Bbia antigens. One sample showed antibodies against all three rDbpAs, and one had antibodies to rDbpA BaA91 and rDbpA Bg40 . Four sera that reacted with two or three rDbpAs showed a strong reaction with one protein, but also some immunoreactivity against the other rDbpAs. All of the control samples were negative against the three rDbpAs (Table 2) .
Immunoblot reactivity in mouse samples. When rDbpA Bg40 was used as the antigen in the immunoblot assay, weak reactions were observed with the infected mouse plasma 4 weeks postinfection with B. garinii. At 8 and 16 weeks postinfection, the pooled plasma reacted positively with rDbpA Bg40 (Fig. 3) . The infected mouse plasma did not react with rDbpA BaA91 or rDbpA Bbia at any time point (data not shown). Plasma from sham-infected mice was immunoblot negative (Fig. 3) .
ELISA. In IgG ELISA, 14 of 14 samples (100%) from patients with NB were positive. Seven of 14 (50%), 7 of 14 (50%), and 6 of 14 (43%) were positive when rDbpA BaA91 , rDbpA Bg40 , and rDbpA Bbia , respectively, were used as antigens (Fig. 4) . Fourteen of the 15 samples (93%) from patients with LA were positive; 12 of 15 (80%), 3 of 15 (20%), and 9 of 15 (60%) were positive with rDbpA BaA91 , rDbpA Bg40 , and rDbpA Bbia , respectively (Fig. 4) . The majority of immunoreactivity was against rDbpA from B. afzelii and B. garinii. Of the 26 positive samples with either rDbpA BaA91 or rDbpA Bg40 , 23 reacted with one antigen only (Fig. 5) . Only three samples "cross-reacted", and their OD values with the two antigens were equally high. One patient only with LA had a high antibody response against rDbpA from B. burgdorferi sensu stricto (Fig. 4C) . This sample also reacted with the other rDbpAs, but these antibody responses were weak positives. Two samples from patients with NB were positive only for rDbpA Bbia . The majority of the 15 positive reactions against rDbpA Bbia were close to the cutoff level (Fig. 4C) .
ELISA of EM patient samples. We also tested serum samples from culture-or PCR-positive EM patients for anti-DbpA antibodies. In IgM ELISA with rDbpA BaA91 or rDbpA Bg40 as an antigen, 1 or 2 of the 23 samples (4 to 9%) at diagnosis and 1 or 2 (4 to 9%) at the convalescence phase, respectively, were positive (data not shown). In IgG ELISA, 3 or 1 of the 23 samples 
DISCUSSION
We analyzed and compared sequences of DbpA from three European isolates of B. burgdorferi sensu lato, B. burgdorferi sensu stricto, B. afzelii, and B. garinii. Compatibly with a previous study (33), we observed high interspecies heterogeneity. Our hypothesis was that the heterogeneity of the amino acid sequences might have major implications for the usefulness of a given antigen in the serodiagnosis of LB. If the antigenic epitopes in the variant proteins were different, the sensitivity of an immunoassay would be low with a single variant antigen only. In the present study, we demonstrate that inclusion of DbpA variants from three pathogenic species of B. burgdorferi as antigens significantly increased the sensitivity of the Western blotting and ELISAs, compared with the use of a single DbpA antigen.
For reliable serodiagnosis of LB, a confirmatory immunoblotting after the ELISA has been advocated. In Europe especially, the use of different species and strains of B. burgdorferi sensu lato as sources of antigens leads to inconsistent results because of variations in the expression of the immunogenic proteins (18, 34) . Furthermore, immunoblotting not only is a tedious procedure in the laboratory routine, but also is prone to subjective interpretations of band intensities. A recent European multicenter study formulated a panel of seven immunoblotting rules to be adopted in relation to the characteristics of LB in local areas (34) . In another European study, exclusion of EBV and cytomegalovirus infections by appropriate serology gave better predictive power than confirmation with immunoblotting after the ELISA (11) . Beyond any doubt, this emphasizes the need for novel methods that would be standardized at least with regard to performance, relevance, techniques, and antigen preparation. Use of recombinant antigens is an option. In the present study, rDbpAs from B. burgdorferi sensu lato isolates seemed to be sensitive and specific antigens in the WB and ELISAs for disseminated LB. Among welldefined patients with LA or NB, up to 93 to 100% of samples reacted positively with rDbpAs. WB results and quantification of immunoreactivities by ELISA provided evidence for the species specificity of serological responses. In the majority of cases with positive reactions against more than one DbpA variant proteins, the immunoreactivity was superior against one DbpA antigen. Moreover, the absence of immunoreactivity in non-Lyme sera indicates specificity of DbpA antigens.
Unfortunately, the low sensitivity of IgM and IgG serology for EM limits the utility of rDbpA as a diagnostic antigen in early stages of LB. This has been the experience with several other recombinant borrelial antigens (27, 28) . Obviously, the immunological properties and/or differences in expression of the DbpA molecule account for the delayed antibody response during the course of Lyme disease. Also, it is unclear at the moment whether early antibiotic treatment of EM patients would have contributed to our inability to detect anti-DbpA antibodies when using convalescent-phase sera.
To our knowledge, only one study has evaluated immune responses to rDbpA in the serodiagnosis of human LB (7). In Italian patients, immune responses to rDbpA from B. burgdorferi sensu stricto 297 were detected in 13% of patients with EM and 35% of those with disseminated LB (NB and LA). In children with suspected LB, by using rDbpA originating from B. burgdorferi sensu stricto N40, we observed the immunoreactivity to be at approximately the same level (unpublished observations). The proportion of samples reacting with rDbpA from B. burgdorferi sensu stricto in the present study is in accord with the previous results. These findings are probably due to heterogeneity of the proteins resulting in differences in the epitope specificity of the antibodies. In the present study, the predominance of immunoreactivity to rDbpA from B. afzelii and B. garinii is compatible with the greater prevalence of these two genospecies compared to that of B. burgdorferi sensu stricto in Europe (24, 41) .
The immunoreactivity to DbpA in experimental murine borreliosis in this study supports the species specificity of LB serology. The antibody response in infected mice corresponds to that in earlier studies, in which detectable antibody levels were seen at 2 to 4 weeks postinfection (9, 14, 15) . Feng et al. (9) observed some cross-reactivity of antibodies against heterologous DbpA. They reported that plasma from mice infected with the B. afzelii PKo strain or B. garinii PBi strain reacted against rDbpA from genetically distant B. burgdorferi sensu stricto N40, yet at significantly lower levels than those against plasma from mice infected with homologous B. burgdorferi sensu stricto N40. These data suggest some degree of crossreactivity among isolates of antigenically divergent B. burgdorferi sensu lato. In fact, this is in line with the observed differences in the immune responses to the DbpA variants in the present study.
A recent study described a novel immunodominant outer surface protein of B. afzelii, Osp17 (22) (42) , with seropositivity of 24 to 36% in patients with early disseminated borreliosis and up to 85% in patients with late disease (30, 42) . It is obvious that inclusion of rDbpAs (Osp17) derived from different strains would increase the sensitivity of the recombinant blot.
The high sequence heterogeneity of DbpA among the three borrelial subspecies raises interesting considerations regarding the potential differences in the interaction between this protein and the host immune system. The DbpA of B. burgdorferi has been suggested to have a biological function (i.e., decorin binding activity) (12, 13) , during the mammalian phase of LB. This ability is believed to be important for promoting colonization by the spirochetes when they penetrate into the skin via a tick bite and adhere to the collagen-associated proteoglycan decorin (15) . Evaluation of the decorin binding activity of our DbpA constructs was beyond the scope of this study. However, the critical lysine residues responsible for this activity (4) were present in all three Finnish human isolates of B. burgdorferi sensu lato examined (data not shown). The heterogeneity of DbpA proteins may also have implications for the vaccine development of this antigen (6, 15, 16) . Although a recent study suggests that conformational epitopes are needed to elicit protective antibodies against homologous and heterologous strains (40) , the present findings on the species specificity of serologic responses to DbpA imply that development of a wide-spectrum vaccine may be more complicated than anticipated.
In conclusion, DbpA seems to be a sensitive and specific antigen for the serodiagnosis of LA or NB, provided that variants from all pathogenic borrelial species are included in the antigen set. This approach may reduce the number of false-negative results. The present findings also imply that DbpA antigens might be used for the species-specific serodiagnosis of LA and NB. These characteristics could be useful at least for epidemiologic purposes, as well as, possibly, prognostic or therapeutic purposes. It has been shown that the three pathogenic borrelial subspecies are preferentially associated with distinct clinical pictures (41) . Moreover, a recent study suggested that even at the subspecies level, certain strains, on the basis of genetic diversity of ospC genes, might cause more invasive or severe disease than other strains (2) . Given the well-known difficulties in detecting borreliae from clinical samples, either by culture or PCR, it can be speculated that knowledge of the causative borrelial subspecies might be beneficial when evaluating the course of the disease and intensity of the antibiotic therapy.
